

# Pharmaceutical Contract Manufacturing Market (3rd Edition), 2021-2030

*Pharmaceutical Contract Manufacturing Market (3rd Edition), 2021-2030*

LONDON, ENGLAND, UNITED KINGDOM, October 8, 2021

/EINPresswire.com/ -- Driven by the COVID-19 pandemic and increasing demand for small molecules, the [pharmaceutical contract manufacturing](#) market is anticipated to witness significant growth over the next decade.

[Roots Analysis](#) has announced the addition of “Pharmaceutical [Contract Manufacturing Market](#) (3rd Edition), 2021-2030” report to its list of offerings.

The report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing industry. Amongst other elements, the report features:

- ▣ A detailed overview of the overall market landscape, featuring an elaborate list of over 450 active CMOs engaged in this domain, along with information on several relevant parameters, such as year of establishment, company size, geographical location of CMOs, type of business segment (active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs)), type of API(s) manufactured (complex, generic and sterile), type of FDF(s) offered (oral solids, liquids / semi-solids, injectables, inhalation and others), type of service(s) offered, type of primary packaging form (blister, tubes, vial / cartridge, ampoule, sachets / pouches / bags, inhalers / nasal sprays, glass / plastic / dropper bottles, pre-filled syringes /

**Example Highlights**

The market is characterized by the presence of both established players and new entrants that offer end-to-end services to pharmaceutical companies.

Pharmaceutical CMOs Distribution by Company Size and HQ <sup>1</sup>	Pharmaceutical CMOs Distribution by Scale of Operation <sup>2</sup>	Pharmaceutical CMOs Distribution by Type of Service(s) Offered

*Insightful graphical summaries, offering diverse perspectives concerning the current market landscape of pharmaceutical contract manufacturing organizations*

*All charts are accompanied by our observations and professional opinions on the market and affiliated trends*

2021 © Roots Analysis

## Pharmaceutical Contract Manufacturing Market

**Example highlights**

Key market drivers, challenges, and opportunities for pharmaceutical contract manufacturing companies worldwide.

<p>Over time, outsourcing has become a popular strategy in the pharmaceutical industry, enabling developers to save costs  <small>Ex-Associate Director, a mid-sized CMO</small></p>	<p>CMOs invest exorbitant amount of money in equipment and technology, and must comply with strict regulatory standards  <small>President and Chief Executive Officer, a large CMO</small></p>	<p>Technical advances, such as the use of robots, process digitization and automation, have notably improved production processes  <small>Chief Executive Officer, a large CMO</small></p>	<p>Adoption of novel technologies are likely to expedite the development of innovative pharmaceutical products  <small>Vice President, a large CMO</small></p>
<p>Several large pharma companies also outsource various aspects of their business operations to optimize internal resource use  <small>Chief Executive Officer, a mid-sized CMO</small></p>	<p>The COVID-19 pandemic has brought a significant increase in the demand for contract manufacturing services  <small>Vice President, a mid-sized CMO</small></p>	<p>Advanced tools, such as network collaboration, impact analysis, scenario planning are important for a resilient supply chain  <small>Director of supply chain, a mid-sized pharmaceutical company</small></p>	<p>Healthcare has witnessed a rise in innovation to overcome the pandemic, mainly related to products development  <small>Vice President Business Development, a mid-sized healthcare company</small></p>
<p>For the more complex drugs, such as HPAPIs, customers tend to rely more on CMOs in Europe and the US, rather than the low-cost nations  <small>Senior Manager, a mid-sized CMO</small></p>	<p>However, for HPAPI, the available capacity to manufacture such drugs is limited, considering the growing demand for such products  <small>Vice President, a mid-sized CMO</small></p>	<p>Larger CMOs have widely dispersed capabilities, thereby, effectively catering to multiple international markets  <small>President, a mid-sized healthcare company</small></p>	<p>The contract services market for parenteral drugs is anticipated to witness significant growth in future, in terms of service revenues  <small>Managing Director, a large CMO</small></p>

2021 © Roots Analysis

## Pharmaceutical Contract Manufacturing

autoinjectors), scale of operation (preclinical, clinical and commercial) and specific location of manufacturing facilities (country-wise).

□ A detailed analysis of various mergers and acquisitions that have taken place in this domain, highlighting the trend in number of companies acquired and geographical distribution of the activity, during the period 2017-2021. Further, it highlights the relationship between deal multiples (based on revenues), number of employees and experience of the acquired firm.

□ A detailed analysis of the recent expansions (since 2017) undertaken by various service providers in order to augment their respective pharmaceutical contract manufacturing service portfolios, based on a several relevant parameters, such as year of expansion, purpose of expansion (capability expansion, capacity expansion, facility expansion, new facility), type of business segment (API(s), FDF(s)), capital invested, scale of operation (clinical, commercial), type of service(s) offered (formulation, manufacturing, packaging), geographical location of facility, and most active players (in terms of number of instances).

□ An estimate of the global, installed capacity for the manufacturing of small-molecule drugs, based on information provided by various industry stakeholders in the public domain. It also features distribution of the available capacity on the basis of scale of operation (clinical and commercial), company size (small, mid-sized and large firms) and key geographical regions (North America, Europe and Asia Pacific).

□ Informed estimates of the annual clinical and commercial demand for small molecule drugs, across key geographical regions.

□ A detailed analysis of pharmaceutical contract manufacturing service providers' capabilities in



different regions, based on several relevant parameters, such as type of business segment, type of service(s) offered and type of packaging form.

□ A detailed analysis of various pharmaceutical contract manufacturing service providers featuring schematic representations, including [A] a heat map analysis, highlighting the distribution of integrated contract service providers (companies offering manufacturing services for both small and large molecules), on the basis of location of their headquarters, year of establishment and number of employees, [B] a geographical landscape analysis, highlighting CMOs that have a wide geographical reach, on the basis of their presence (manufacturing facilities) across various regions, and [C] a grid representation, highlighting the global and regional trend of API and FDF outsourcing services, based on the location of headquarters of the company, number of employees, type of business segment, type of service(s) offered and scale of operation.

□ A detailed discussion on various guidelines laid down by major regulatory bodies, across different countries, featuring an elaborative assessment of over 450 CMOs engaged in this domain, along with information on their operational approvals, certifications received, and relative popularity of the key regulatory body. Additionally, the chapter features an insightful multi-dimensional bubble analysis, presenting a comparison of the current regulatory scenario in key geographies.

□ Elaborate profiles of key players engaged in offering pharmaceutical contract manufacturing services. Each profile features a brief overview of the company, along with information on its financial performance (if available), service(s) portfolio, manufacturing facilities and capabilities, recent developments and an informed future outlook.

□ A case study highlighting a comparison of the key characteristics of large and small molecule drugs, along with information on the steps involved in their respective manufacturing processes.

□ A qualitative analysis highlighting the various factors that need to be taken into consideration by pharmaceutical drug developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.

□ A detailed analysis capturing the key parameters and trends that are likely to influence the future of the pharmaceutical contract manufacturing market, under an elaborate SWOT framework. Further, it presents a schematic Harvey ball analysis highlighting the relative impact of each SWOT parameter on the overall pharmaceutical industry.

□ A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below):

□ Type of Business Segment

□ API

BDF

Type of API Manufactured

Generics

Originator

Type of FDF Offered

Oral Solids

Parenteral

Others

Scale of Operation

Clinical

Commercial

Type of Packaging Form Offered

Bottles

Blisters

Injectables

Others

Type of End-User

Small

Mid-sized

Large

Region

North America

Europe

Asia-Pacific

Latin America

Middle East and North Africa

Key companies covered in the report

AMRI Global

Altasciences

Cambrex

Catalent

DPT Laboratories

Thermo Fisher Scientific

Zenova Group

Almac Group

Corden Pharma

□Bresenius Kabi  
□Glatt  
□Hovione  
□Recipharm  
□Siegfried  
□CMIC Group  
□Nectar Lifesciences  
□Syngene  
□WuXi AppTec

For more information, please click on the following link:

[https://www.rootsanalysis.com/reports/view\\_document/pharmaceutical-contract-manufacturing-market/191.html](https://www.rootsanalysis.com/reports/view_document/pharmaceutical-contract-manufacturing-market/191.html) or email [sales@rootsanalysis.com](mailto:sales@rootsanalysis.com)

#### Other Recent Offerings

1. Vaccine Contract Manufacturing Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030
2. Pharmaceutical Contract Research Services Market: Industry Trends and Global Forecasts, 2021-2030
3. Biopharmaceutical Contract Manufacturing Market (4th Edition): Industry Trends and Global Forecasts, 2021-2030

#### About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you'd like help with your growing business needs, get in touch at [info@rootsanalysis.com](mailto:info@rootsanalysis.com)

#### Contact Information

Roots Analysis Private Limited  
Ben Johnson  
+1 (415) 800 3415  
+44 (122) 391 1091  
[Ben.johnson@rootsanalysis.com](mailto:Ben.johnson@rootsanalysis.com)

Gaurav Chaudhary

Roots Analysis  
+1 415-800-3415

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/553354235>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.